Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

A Children's Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Blood (2024) 144 (Supplement 1): 2808.1.

https://doi.org/10.1182/blood-2024-203724

Published: 2024

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

Expansion of GATA1 -Mutant Clones in Blood Samples of Patients with Transient Abnormal Myelopoiesis (TAM) during Clinical Follow up Heralds Transformation to Myeloid Leukemia Associated with Down Syndrome (ML-DS)

Jian Chen, Ryan Ripsman, Rose Vernier, Astra Schwertschkow, Adam Shlien, Johann K. Hitzler

Blood (2024) 144 (Supplement 1): 6137.

https://doi.org/10.1182/blood-2024-204116

Published: 2024

Journal Articles

Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia

Sonali P Barwe, Meredith Tavenner, Patrick Van Berkel, Aimy Sebastian, Rhonda E. Ries, Soheil Meshinchi, Johann K. Hitzler, Yana Pikman, Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2024) 144 (Supplement 1): 209.

https://doi.org/10.1182/blood-2024-211364

Published: 2024

Journal Articles

Inflammatory Signatures Define a New High-Risk T-Lineage ALL Subtype

Blood (2023) 142 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2023-182412

Published: 2023

Journal Articles

The Challenge of Treating Relapsed Myeloid Leukemia in Children with Down Syndrome - a Targeted Analysis Using Patient-Derived Xenograft Models

Jian Chen, Mohamed M. Abdelhaleem, Johann K. Hitzler

Blood (2023) 142 (Supplement 1): 5743.

https://doi.org/10.1182/blood-2023-187455

Published: 2023

Journal Articles

Integrative Genome and Transcriptome Sequencing Analysis Indicates Genetic and Epigenetic Dysregulation in DS-AML

Xiaotu Ma, Rhonda E Ries, Quang Tran, Yanling Liu, Pandurang Kolekar, Ramzi Alsallaq, Zhikai Liang, Timothy Shaw, Meghana Devineni, Anne Deslattes Mays, Ching Lau, Johann K. Hitzler, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 4117.

https://doi.org/10.1182/blood-2023-186456

Published: 2023

Journal Articles

Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse

Joerg Krueger, Johann K Hitzler, Stephanie Audrey Mourad, Mylene Bassal, Elizabeth Cairney, Bruce N. Crooks, Angela Punnett, Sarah Alexander, Muhammad Ali, Henrique Bittencourt, James A. Whitlock, Sumit Gupta

Blood (2021) 138 (Supplement 1): 4820.

https://doi.org/10.1182/blood-2021-153262

Published: 2021

Journal Articles

How Important Are in-Person Clinic Visits during Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia?

Ron Rabinowicz, Johann K Hitzler, Angela Punnett

Blood (2021) 138 (Supplement 1): 2998.

https://doi.org/10.1182/blood-2021-150142

Published: 2021

Journal Articles

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Amanda M. Li, Karen R Rabin, John Kairalla, Cindy Wang, Meenakshi Devidas, Olga Militano, Maki Okada, Johann K Hitzler, Anne L Angiolillo, Elizabeth A. Raetz, Mignon L. Loh, Sumit Gupta, Rachel E. Rau

Blood (2021) 138 (Supplement 1): 2304.

https://doi.org/10.1182/blood-2021-148967

Published: 2021

Journal Articles

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-143165

Published: 2020

Journal Articles

A Human Model of Down Syndrome Associated Leukemia Reveals Different Cell of Origins for Initiation and Progression

Elvin Wagenblast, PhD, Joana Araújo, MD, Olga I. Gan, PhD, Sarah K Cutting, Alex Murison, Jessica L. McLeod, Gabriela Krivdova, BSc, Maria Azkanaz, Sabrina A Smith, Johann K Hitzler, MD, John E. Dick, PhD FRS, Eric R Lechman, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-135867

Published: 2020

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

Understanding Pre-Leukemia in Trisomy 21 Human HSC and Modeling Progression Towards Down Syndrome Associated Leukemia Using CRISPR/Cas9 at Single Cell Resolution

Elvin Wagenblast, PhD, Olga I. Gan, PhD, Maria Azkanaz, Sabrina A. Smith, Joana Araújo, MD, Lorien Shakib, Jessica L. McLeod, Gabriela Krivdova, Johann K. Hitzler, MD, Eric R. Lechman, PhD, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 2531.

https://doi.org/10.1182/blood-2019-129259

Published: 2019

Journal Articles

The Clonal Hematopoietic Spectrum of Down Syndrome and ML-DS

R. Spencer Tong, BA, Wing Hing Wong, BSc, David R. O'Leary, Kathleen S. Jay, MS, RN, PNP-BC, D. Katherine Grange, MD, Jason Berman, MD, Johann K. Hitzler, MD, Todd E Druley, MD PhD

Blood (2018) 132 (Supplement 1): 3839.

https://doi.org/10.1182/blood-2018-99-120168

Published: 2018

Journal Articles

Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome

Jian Chen, PhD, Yue Li, MD MSC, Fouad Yousif, Sagi Abelson, PhD, Sanaz Manteghi, PhD, John D. McPherson, PhD, Johann K. Hitzler, MD

Blood (2018) 132 (Supplement 1): 442.

https://doi.org/10.1182/blood-2018-99-117198

Published: 2018

Journal Articles

Functional and Molecular Consequences of Trisomy 21 on Human Fetal Hematopoiesis

Elvin Wagenblast, PhD, Gabriela Krivdova, BSc, MSc, Olga I. Gan, PhD, Johann K. Hitzler, MD, John E. Dick, PhD, Eric R. Lechman, PhD

Blood (2018) 132 (Supplement 1): 1317.

https://doi.org/10.1182/blood-2018-99-119734

Published: 2018

Journal Articles

High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada

Sumit Gupta, MD, Sarah Alexander, MD, Sue Zupanec, RN, Uma Athale, MDMBBS,MSc, Mylene Bassal, MD, Ethan Edwards, Paul J. Gibson, MD, Donna Johnston, MDFRCPC, Stacey Marjerrison, MD, Alexander Zorzi, MD, Johann K. Hitzler, MD, Ahmed Naqvi, MD, Angela Punnett, MD, James A. Whitlock, MD, Stephan A. Grupp, MD PhD, Shannon L. Maude, MD PhD, Joerg Krueger, MD

Blood (2018) 132 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2018-99-115593

Published: 2018

Journal Articles

Inactivation of Stage-Specific B-Cell Commitment Genes Generates Distinct Molecular Subtypes of BCR-ABL1 Lymphoblastic Leukemia

Jaeseung C. Kim, MSc, Michelle Chan-Seng-Yue, Gavin W. Wilson, PhD, Andrea Arruda, Karen Ng, Olga I. Gan, PhD, Stephanie M. Dobson, PhD, Paul M. Krzyzanowski, PhD, Johann K. Hitzler, MD, Anne Tierens, MD PhD, John E. Dick, PhD, Mark D. Minden, MD PhD, John D. McPherson, PhD, Faiyaz Notta, PhD

Blood (2018) 132 (Supplement 1): 569.

https://doi.org/10.1182/blood-2018-99-116981

Published: 2018

Journal Articles

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Jeffrey W. Taub, Jason N. Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David Head, Susana Raimondi, Betsy Hirsch, Yubin Ge, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis

Blood (2017) 129 (25): 3304–3313.

https://doi.org/10.1182/blood-2017-01-764324

Published: 2017

Includes: Supplemental data

NARROW

A Children's Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Expansion of GATA1 -Mutant Clones in Blood Samples of Patients with Transient Abnormal Myelopoiesis (TAM) during Clinical Follow up Heralds Transformation to Myeloid Leukemia Associated with Down Syndrome (ML-DS)

Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia

Inflammatory Signatures Define a New High-Risk T-Lineage ALL Subtype

The Challenge of Treating Relapsed Myeloid Leukemia in Children with Down Syndrome - a Targeted Analysis Using Patient-Derived Xenograft Models

Integrative Genome and Transcriptome Sequencing Analysis Indicates Genetic and Epigenetic Dysregulation in DS-AML

Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse

How Important Are in-Person Clinic Visits during Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia?

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

A Human Model of Down Syndrome Associated Leukemia Reveals Different Cell of Origins for Initiation and Progression

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Understanding Pre-Leukemia in Trisomy 21 Human HSC and Modeling Progression Towards Down Syndrome Associated Leukemia Using CRISPR/Cas9 at Single Cell Resolution

The Clonal Hematopoietic Spectrum of Down Syndrome and ML-DS

Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome

Functional and Molecular Consequences of Trisomy 21 on Human Fetal Hematopoiesis

High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada

Inactivation of Stage-Specific B-Cell Commitment Genes Generates Distinct Molecular Subtypes of BCR-ABL1 Lymphoblastic Leukemia

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only